A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3, PIVOTAL STUDY WITH AN OPEN-LABEL EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PARTICIPANTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG) ANTIBODY-ASSOCIATED DISEASE (MOG-AD)
Details
Age
Adult
Type of Study
Treatment
Locations
Brain Imaging Center (BIC)
University of Colorado Hospital
Principal Investigator
Jeffrey Bennett, MD, PhD
Study ID
Protocol Number: 21-3747
More information available at ClinicalTrials.gov: NCT05063162
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers